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Identity 
Other names: central neurofibromatosis; bilateral 
acoustic neurofibromatosis; bilateral acoustic 
neurinoma; bilateral acoustic schwannomas. 
Inheritance: autosomal dominant with almost 
complete penetrance; frequency is 3/105 newborns; 
neomutation represent 50% of cases; variable 
expressivity from mild disease through life (Gardner 
type) to severe condition at young age (Wishart type: 
with more than 3 tumours). 
Clinics 
NF2 is an hamartoneoplastic syndrome; hamartomas 
are localized tissue proliferations with faulty 
differentiation and mixture of component tissues; they 
are heritable malformations that have a potential 
towards neoplasia. 
Phenotype and clinics 
- Bilateral vestibular (8th cranial pair) schwannomas; 
other central or peripheral nerve schwannomas; 
meningiomas; ependymomas. 
- Hearing loss (average age 20 yrs), tinnitus, imbalance, 
headache, cataract in 50%, facial paralysis. 
- Café-au-lait spots and cutaneous and peripheral 
neurofibromas may be present, but less extensively 
than in neurofibromatosis type 1. 
Neoplastic risk 
NF2 cases represent about 5 % of schwannomas and 
meningiomas (i.e. risk increased by 2000), appearing at 
the age of 20, while they are found in the general 
population at the age of 50 and over. 
Prognosis 
These tumours are usually benign, but their location 
within the central nervous system give them a grave 
prognosis; patients with the Wishart severe form 





Chromosome 22 loss is very frequent both in sporadic 
and in NF2 schwannomas and meningiomas. 
Genes involved and Proteins 
NF2 (neurofibromin 2) 
Location: 22q12 
DNA/RNA 
Description: 16 exons. 
Protein 
Description: contains a membrane binding domain and 
a helix binding to actin of the cytoskeleton. 
Expression: wide. 
Function: membrane-cytoskeleton anchor; should be a 
tumour suppressor. 
Homology 
Band 4.1 family. 
Mutations 
Germinal: germ-line mutations in NF2 patients lead to 
protein truncation; splice-site or missense mutations are 
also found; phenotype-genotype correlations are 
observed (i.e. that severe phenotype are found in cases 
with protein truncations rather than those with amino 
acid substitution). 
Somatic: mutation and allele loss events in tumours in 
neurofibromatosis type 2 and in sporadic schwannomas 
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and meningiomas are in accordance with the two-hit 
model for neoplasia. 
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